Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 Jun 28. doi: 10.1038/s41591-018-0097-4. [Epub ahead of print]

PMID:
29955182
2.

Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 Jun 28. doi: 10.1038/s41591-018-0098-3. [Epub ahead of print]

PMID:
29955181
3.

Mass cytometry of Hodgkin lymphoma reveals a CD4+ exhausted T-effector and T-regulatory cell rich microenvironment.

Cader FZ, Schackmann RCJ, Hu X, Wienand K, Redd R, Chapuy B, Ouyang J, Paul N, Gjini E, Lipschitz M, Armand P, Wu D, Fromm JR, Neuberg D, Liu XS, Rodig SJ, Shipp MA.

Blood. 2018 Jun 7. pii: blood-2018-04-843714. doi: 10.1182/blood-2018-04-843714. [Epub ahead of print]

PMID:
29880615
4.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30. Erratum in: Nat Med. 2018 Jun 28;:. Nat Med. 2018 Jun 28;:.

PMID:
29713087
5.

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA.

Blood. 2017 Jun 8;129(23):3071-3073. doi: 10.1182/blood-2017-01-764209. Epub 2017 Mar 29.

6.

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ.

Cancer Immunol Res. 2016 Nov;4(11):910-916. Epub 2016 Oct 13.

7.

Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets.

Norberg E, Lako A, Chen PH, Stanley IA, Zhou F, Ficarro SB, Chapuy B, Chen L, Rodig S, Shin D, Choi DW, Lee S, Shipp MA, Marto JA, Danial NN.

Cell Death Differ. 2017 Feb;24(2):251-262. doi: 10.1038/cdd.2016.116. Epub 2016 Oct 21.

8.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J.

J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.

9.

Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.

Hohloch K, Zeynalova S, Chapuy B, Pfreundschuh M, Loeffler M, Ziepert M, Feller AC, Trümper L, Hasenclever D, Wulf G, Schmitz N.

Ann Hematol. 2016 Jun;95(7):1121-8. doi: 10.1007/s00277-016-2671-5. Epub 2016 May 11.

PMID:
27165090
10.

NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004. doi: 10.1073/pnas.1602069113. Epub 2016 May 9.

11.

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA.

J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.

12.

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.

Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, Lee L, Viswanathan A, Horowitz N, Neuberg D, Crum CP, Lindeman NL, Kuo F, Ligon AH, Freeman GJ, Hodi FS, Shipp MA, Rodig SJ.

JAMA Oncol. 2016 Apr;2(4):518-22. doi: 10.1001/jamaoncol.2015.6326.

PMID:
26913631
13.

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.

Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA.

Blood. 2016 May 5;127(18):2203-13. doi: 10.1182/blood-2015-09-672352. Epub 2016 Jan 15.

14.

Targetable genetic features of primary testicular and primary central nervous system lymphomas.

Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA.

Blood. 2016 Feb 18;127(7):869-81. doi: 10.1182/blood-2015-10-673236. Epub 2015 Dec 23.

15.

Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone.

Koch R, Aung T, Vogel D, Chapuy B, Wenzel D, Becker S, Sinzig U, Venkataramani V, von Mach T, Jacob R, Truemper L, Wulf GG.

Clin Cancer Res. 2016 Jan 15;22(2):395-404. doi: 10.1158/1078-0432.CCR-15-0577. Epub 2015 Sep 14.

16.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM.

Cancer Cell. 2015 Jul 13;28(1):29-41. doi: 10.1016/j.ccell.2015.06.005.

17.

The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.

Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Velasco-Herrera Mdel C, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP.

Cell. 2015 Apr 9;161(2):319-32. doi: 10.1016/j.cell.2015.02.043. Epub 2015 Apr 2.

18.

Resolving the daratumumab interference with blood compatibility testing.

Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, Doshi P, Kaufman RM.

Transfusion. 2015 Jun;55(6 Pt 2):1545-54. doi: 10.1111/trf.13069. Epub 2015 Mar 12.

PMID:
25764134
19.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

20.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

21.

Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ.

J Mol Diagn. 2015 Jan;17(1):19-30. doi: 10.1016/j.jmoldx.2014.08.006. Epub 2014 Nov 7.

22.

MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.

Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczyński P.

Biochim Biophys Acta. 2014 Dec;1846(2):457-67. doi: 10.1016/j.bbcan.2014.08.006. Epub 2014 Sep 6. Review.

PMID:
25199984
23.

Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ.

Am J Surg Pathol. 2014 Dec;38(12):1715-23. doi: 10.1097/PAS.0000000000000297.

24.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

25.

Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA.

Clin Cancer Res. 2014 May 15;20(10):2674-83. doi: 10.1158/1078-0432.CCR-13-3007. Epub 2014 Mar 7.

26.

Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma.

Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B, Wenzel D, Lahmann M, Güntsch A, Kiecke C, Becker S, Hupfeld T, Venkataramani V, Ziepert M, Opitz L, Klapper W, Trümper L, Wulf GG.

Blood. 2014 Apr 3;123(14):2189-98. doi: 10.1182/blood-2013-08-523886. Epub 2014 Feb 21.

27.

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE.

Cancer Cell. 2013 Dec 9;24(6):777-90. doi: 10.1016/j.ccr.2013.11.003. Erratum in: Cancer Cell. 2014 Apr 14;25(4):545-6.

28.

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.

Cancer Cell. 2013 Jun 10;23(6):826-38. doi: 10.1016/j.ccr.2013.05.002.

29.

Intracellular ATP-binding cassette transporter A3 is expressed in lung cancer cells and modulates susceptibility to cisplatin and paclitaxel.

Overbeck TR, Hupfeld T, Krause D, Waldmann-Beushausen R, Chapuy B, Güldenzoph B, Aung T, Inagaki N, Schöndube FA, Danner BC, Truemper L, Wulf GG.

Oncology. 2013;84(6):362-70. doi: 10.1159/000348884. Epub 2013 May 15.

PMID:
23689165
30.

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ.

Clin Cancer Res. 2013 Jul 1;19(13):3462-73. doi: 10.1158/1078-0432.CCR-13-0855. Epub 2013 May 14.

31.

Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.

Hupfeld T, Chapuy B, Schrader V, Beutler M, Veltkamp C, Koch R, Cameron S, Aung T, Haase D, Larosee P, Truemper L, Wulf GG.

Br J Haematol. 2013 Apr;161(2):204-13. doi: 10.1111/bjh.12246. Epub 2013 Feb 21.

PMID:
23432194
32.

Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN.

Cancer Cell. 2012 Oct 16;22(4):547-60. doi: 10.1016/j.ccr.2012.08.014.

33.

Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.

Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA.

Cancer Cell. 2012 Sep 11;22(3):359-72. doi: 10.1016/j.ccr.2012.07.014.

34.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

35.

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas.

Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ.

PLoS One. 2012;7(4):e33813. doi: 10.1371/journal.pone.0033813. Epub 2012 Apr 12.

36.

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.

Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84. doi: 10.1073/pnas.1121343109. Epub 2012 Feb 17.

37.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

38.

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.

Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M.

Nature. 2012 Jan 5;481(7379):90-3. doi: 10.1038/nature10688.

39.

Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.

Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trümper L, Wulf GG.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41. doi: 10.1073/pnas.1102855108. Epub 2011 Aug 25.

40.

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.

Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG.

Br J Haematol. 2011 Feb;152(4):401-12. doi: 10.1111/j.1365-2141.2010.08526.x.

PMID:
21689083
41.

The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.

Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T.

Haematologica. 2010 Dec;95(12):2056-62. doi: 10.3324/haematol.2010.025767. Epub 2010 Sep 7.

42.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA.

Blood. 2010 Oct 28;116(17):3268-77. doi: 10.1182/blood-2010-05-282780. Epub 2010 Jul 13.

43.

ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.

Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG.

Haematologica. 2009 Nov;94(11):1528-36. doi: 10.3324/haematol.2009.008631.

44.

A rare cause of sudden cardiac arrest: primary cardiac lymphoma.

Dellas C, Chapuy B, Schweyer S, Hasenfuss G, Hünlich M.

Clin Res Cardiol. 2009 Aug;98(8):509-11. doi: 10.1007/s00392-009-0034-0. Epub 2009 Jun 5. No abstract available.

45.

Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3.

Piesche M, Hildebrandt Y, Chapuy B, Wulf GG, Trümper L, Schroers R.

Vaccine. 2009 Jul 23;27(34):4718-23. doi: 10.1016/j.vaccine.2009.05.010. Epub 2009 May 27.

PMID:
19446593
46.

Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.

Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, Schweyer S, Kosari F, Klapper W, Truemper L, Wulf GG.

Leukemia. 2008 Aug;22(8):1576-86. doi: 10.1038/leu.2008.103. Epub 2008 May 8.

PMID:
18463677
47.

AP-1 and AP-3 mediate sorting of melanosomal and lysosomal membrane proteins into distinct post-Golgi trafficking pathways.

Chapuy B, Tikkanen R, Mühlhausen C, Wenzel D, von Figura K, Höning S.

Traffic. 2008 Jul;9(7):1157-72. doi: 10.1111/j.1600-0854.2008.00745.x. Epub 2008 Apr 9.

48.

Self-tolerance of human natural killer cells lacking self-HLA-specific inhibitory receptors.

Hasenkamp J, Borgerding A, Uhrberg M, Falk C, Chapuy B, Wulf G, Jung W, Trümper L, Glass B.

Scand J Immunol. 2008 Mar;67(3):218-29. doi: 10.1111/j.1365-3083.2007.02058.x. Epub 2008 Jan 22.

49.

Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma?

Chapuy B, Hohloch K, Trümper L.

Biotechnol J. 2007 Nov;2(11):1435-43. Review.

PMID:
17886241
50.

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG.

J Clin Invest. 2007 Sep;117(9):2611-20.

Supplemental Content

Loading ...
Support Center